<DOC>
	<DOCNO>NCT02314143</DOCNO>
	<brief_summary>This three-arm , open-label , randomised Phase II study evaluate whether different sequence dabrafenib trametinib monotherapies upfront combination impact translational clinical activity subject BRAF mutant metastatic unresectable stage IIIc IV melanoma . Both dabrafenib trametinib demonstrate clinical activity monotherapies combination BRAF-mutant melanoma . However , duration response seem limited due acquire drug resistance . The goal protocol study sequential effect BRAF MEK inhibition skin , blood tumour biomarkers study correlation biomarkers response treatment intrapatient toxicity . Approximately 54 eligible subject randomise ratio 1:1:1 one three treatment arm .</brief_summary>
	<brief_title>Phase II Biomarker Study Comparing Combination BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus Combination After Monotherapy With Dabrafenib Trametinib</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Dabrafenib</mesh_term>
	<criteria>Participant sign write informed consent ; Participants age &gt; =18 year ; Participants histologically confirm cutaneous melanoma either Stage IIIc ( unresectable ) Stage IV ( metastatic ) ( accord American Joint Committee Cancer [ AJCC ] stag 7th edition ) . BRAF ( protooncogene BRaf ) V600E/K mutationpositive confirm local laboratory . Accessible melanoma tumour biopsy ( locally advance primary melanoma metastasis ) Measurable disease accord Response Evaluation Criteria Solid Tumours ( RECIST 1.1 ) biopsied lesion . All prior anticancer treatmentrelated toxicity ( except alopecia ) must &lt; = Grade 1 accord Common Terminology Criteria Adverse Events version 4 ( CTCAE version 4.0 ) time randomisation . Able swallow retain orally administer medication clinically significant gastrointestinal abnormality may alter absorption malabsorption syndrome major resection stomach bowel . Women childbearing potential must negative serum pregnancy test within 14 day prior randomisation agree use effective contraception , throughout treatment period , 4 month last dose study treatment . Eastern Cooperative Oncology Group ( ECOG ) Performance Status score 0 1 . Adequate baseline organ function define : absolute neutrophil count &gt; = 1.2 Ã— 109/Liters ( L ) ; Haemoglobin &gt; = 9 gram ( g ) /Deciliter ( dL ) ; Platelet count &gt; = 75 x 109/L ; prothrombin time ( PT ) / international normalize ratio ( INR ) partial thromboplastin time ( PTT ) &lt; = 1.5 x Upper limit normal ( ULN ) ; Albumin &gt; = 2.5 g/dL ; Total bilirubin &lt; = 1.5 x ULN ; aspartate aminotransferase ( AST ) alanine transaminase ( ALT ) &lt; = 2.5 x ULN ; Calculated creatinine clearance &gt; =50 mL/min ; Left Ventricular Ejection fraction ( LVEF ) &gt; = Lower limit normal ( LLN ) Echocardiogram ( ECHO ) Prior treatment BRAF MEK inhibitor Any major surgery , extensive radiotherapy , chemotherapy delay toxicity , biologic therapy , immunotherapy within 21 day prior randomisation and/or daily weekly chemotherapy without potential delayed toxicity within 14 day prior randomisation . Taken investigational drug within 28 day 5 halflives ( minimum 14 day ) , whichever short , prior randomisation Current use prohibit medication . Refusal tumour skin biopsy . History another malignancy . Any serious and/or unstable preexist medical condition ( aside malignancy exception specify ) , psychiatric disorder , condition could interfere participant 's safety , obtain informed consent , compliance study procedure . Known Human Immunodeficiency Virus ( HIV ) , Hepatitis B Virus ( HBV ) , Hepatitis C Virus ( HCV ) infection ( exception chronic clear HBV HCV infection allow ) . A history glucose6phosphate dehydrogenase ( G6PD ) deficiency . Brain metastasis exclude unless : All know lesion previously treat surgery stereotactic surgery ( wholebrain radiation allow unless give definitive treatment surgery stereotactic surgery ) , OR Brain lesion ( ) , still present , must confirm stable ( i.e. , increase lesion size ) &gt; = 12 week prior randomisation ( stability must confirm two consecutive magnetic resonance image ( MRI ) compute tomography ( CT ) scan contrast , AND Asymptomatic corticosteroid requirement &gt; = 4 week prior randomisation , AND No enzyme induce anticonvulsant &gt; = 4 week prior randomisation . A history evidence cardiovascular risk include follow : LVEF &lt; LLN ; A QT interval correct heart rate use Bazett 's formula ( QTcB ) &gt; = 480 millisecond ( msec ) ; A history evidence current clinically significant uncontrolled arrhythmia ; Exception : Participants atrial fibrillation control &gt; 30 day prior randomisation eligible ; A history ( within 6 month prior randomisation ) acute coronary syndrome ( include myocardial infarction unstable angina ) , coronary angioplasty ; A history evidence current &gt; = Class II congestive heart failure define New York Heart Association ( NYHA ) guideline ; Treatment refractory hypertension define blood pressure systolic &gt; 140 millimetre mercury ( mmHg ) and/or diastolic &gt; 90 mmHg control antihypertensive therapy ; Participants intracardiac defibrillator permanent pacemaker ; Known cardiac metastasis ; Abnormal cardiac valve morphology ( &gt; =grade 2 ) document echocardiogram ( Participants grade 1 abnormality [ i.e. , mild regurgitation/stenosis ] enter study ) . Participants moderate valvular thickening enter study . A history current evidence/risk retinal vein occlusion ( RVO ) central serous retinopathy ( CSR ) include : Presence predispose factor RVO CSR ( e.g. , uncontrolled glaucoma ocular hypertension , uncontrolled hypertension , uncontrolled diabetes mellitus , history hyperviscosity hypercoagulability syndrome ) ; Visible retinal pathology assess ophthalmic examination consider risk factor RVO CSR : Evidence new optic disc cupping ; Evidence new visual field defect automate perimetry ; Intraocular pressure &gt; 21 mmHg measure tonography . Known immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate study treatment , excipients , and/or dimethyl sulfoxide ( DMSO ) . Pregnant lactating female Interstitial lung disease pneumonitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>dabrafenib</keyword>
	<keyword>MEK</keyword>
	<keyword>trametinib</keyword>
	<keyword>BRAF</keyword>
	<keyword>melanoma</keyword>
	<keyword>Oncology</keyword>
</DOC>